+关注
DDZ
暂无个人介绍
IP属地:广东
23
关注
0
粉丝
0
主题
0
勋章
主贴
热门
DDZ
2020-04-29
$吉利德科学(GILD)$
有效和特效应该还是有些区别,对吗?
DDZ
2020-03-11
$吉利德科学(GILD)$
请问美股分红像A股一样自动到账吗?
DDZ
2020-03-13
$吉利德科学(GILD)$
请问知道什么时候能拿到3月12日的分红吗?
DDZ
2020-05-21
$康希诺生物-B(06185)$
做药本来就是周期长
DDZ
2020-05-21
$康希诺生物-B(06185)$
什么情况?
DDZ
2023-03-16
不知道收到邀请的个人和公司有反馈吗?
百度集团大幅跳水!正式推出大语言模型“文心一言”
DDZ
2020-03-17
50%成功率不差吧
“人民的希望”瑞德西韦让业界专家大失所望!
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3491802181757368,"uuid":"3491802181757368","gmtCreate":1528708161275,"gmtModify":1528708161275,"name":"DDZ","pinyin":"ddz","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":23,"tweetSize":7,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.11","exceedPercentage":"93.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":650107841,"gmtCreate":1678951431083,"gmtModify":1678952120266,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"不知道收到邀请的个人和公司有反馈吗?","listText":"不知道收到邀请的个人和公司有反馈吗?","text":"不知道收到邀请的个人和公司有反馈吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650107841","repostId":"1112765790","repostType":2,"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":953081940,"gmtCreate":1590061243580,"gmtModify":1704191668779,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>做药本来就是周期长","listText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>做药本来就是周期长","text":"$康希诺生物-B(06185)$做药本来就是周期长","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/953081940","isVote":1,"tweetType":1,"viewCount":1528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":959755597,"gmtCreate":1590038875619,"gmtModify":1704191578992,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>什么情况?","listText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>什么情况?","text":"$康希诺生物-B(06185)$什么情况?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/959755597","isVote":1,"tweetType":1,"viewCount":1259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":924067429,"gmtCreate":1588168467461,"gmtModify":1704366734688,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>有效和特效应该还是有些区别,对吗?","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>有效和特效应该还是有些区别,对吗?","text":"$吉利德科学(GILD)$有效和特效应该还是有些区别,对吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/924067429","isVote":1,"tweetType":1,"viewCount":1880,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":964434713,"gmtCreate":1584442921432,"gmtModify":1704354152797,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"50%成功率不差吧","listText":"50%成功率不差吧","text":"50%成功率不差吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/964434713","repostId":"1150330379","repostType":2,"repost":{"id":"1150330379","pubTimestamp":1584440319,"share":"https://www.laohu8.com/m/news/1150330379?lang=&edition=full","pubTime":"2020-03-17 18:18","market":"us","language":"zh","title":"“人民的希望”瑞德西韦让业界专家大失所望!","url":"https://stock-news.laohu8.com/highlight/detail?id=1150330379","media":"全球医生组织 ","summary":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!\n这是最新传播方式认知:\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染","content":"<p><b>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!</b></p>\n<p><b>这是最新传播方式认知:</b></p>\n<p><img src=\"https://static.tigerbbs.com/5178d780395c6aeebadc23d7d1d846c3\"></p>\n<p>根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据,给出最乐观说法是「好坏参半或不及50%效果」。</p>\n<p>华尔街资深分析师表示在评估该项12名患者临床试验报告数据后,得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要!</p>\n<p>相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学,临床病程和病毒学特征,包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的,确诊患者是从钻石公主号游轮接回来的患者。</p>\n<p>该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验,结果表明患者在疾病确诊后第二周出现恶化迹象。」</p>\n<p><b>具体讲,与未接受瑞德西韦治疗的患者相比,接受该药治疗患者的给氧需求,发烧和病毒感染症状改善之间没有「明显时间关联性」。</b></p>\n<p>该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险),这表明该抗病毒治疗效果需要更长时间监测和观察。</p>\n<p>随着疫情全球大流行爆发,寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者,预期1-2月后才能初步评估安全性。</p>\n<p>吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前,在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品,本月底或下月初陆续还会有相关结果报道。</p>\n<p>业界专家认为新药临床试验,特别涉及目前重大疫情,所有试验药品和每项验证结果都会被反复仔细研究,寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望),包括最初个案例也会作为有价值线索分析。</p>\n<p>美国联邦政府的疫情特别行动小组专家指出,该论文尚未经过同行评审,试验结果还需要最终评估。FDA目前无法接受这样的数据审评。</p>\n<p>该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些;大约42%的患者不需要住院治疗;但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展,仍有待研究」。</p>\n<p>还有业界人士提示该试验结果未经同行评审,在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药,包括类固醇激素和抗生素等。</p>\n<p>此外,吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说,该药应尽快给予患者以避免病情恶化,有可能产生一定效果。</p>\n<p>总之,鉴于目前临床试验小样本量和混合其他药品作用,凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度,最终是否止步于III期试验或「被流产」都是未知数。</p>","source":"lsy1584440308046","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“人民的希望”瑞德西韦让业界专家大失所望!</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“人民的希望”瑞德西韦让业界专家大失所望!\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-03-17 18:18 北京时间 <a href=https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg><strong>全球医生组织 </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!\n这是最新传播方式认知:\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据,给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后,得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要!\n相关...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150330379","content_text":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!\n这是最新传播方式认知:\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据,给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后,得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要!\n相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学,临床病程和病毒学特征,包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的,确诊患者是从钻石公主号游轮接回来的患者。\n该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验,结果表明患者在疾病确诊后第二周出现恶化迹象。」\n具体讲,与未接受瑞德西韦治疗的患者相比,接受该药治疗患者的给氧需求,发烧和病毒感染症状改善之间没有「明显时间关联性」。\n该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险),这表明该抗病毒治疗效果需要更长时间监测和观察。\n随着疫情全球大流行爆发,寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者,预期1-2月后才能初步评估安全性。\n吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前,在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品,本月底或下月初陆续还会有相关结果报道。\n业界专家认为新药临床试验,特别涉及目前重大疫情,所有试验药品和每项验证结果都会被反复仔细研究,寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望),包括最初个案例也会作为有价值线索分析。\n美国联邦政府的疫情特别行动小组专家指出,该论文尚未经过同行评审,试验结果还需要最终评估。FDA目前无法接受这样的数据审评。\n该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些;大约42%的患者不需要住院治疗;但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展,仍有待研究」。\n还有业界人士提示该试验结果未经同行评审,在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药,包括类固醇激素和抗生素等。\n此外,吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说,该药应尽快给予患者以避免病情恶化,有可能产生一定效果。\n总之,鉴于目前临床试验小样本量和混合其他药品作用,凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度,最终是否止步于III期试验或「被流产」都是未知数。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965759396,"gmtCreate":1584084281015,"gmtModify":1704352949031,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问知道什么时候能拿到3月12日的分红吗?","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问知道什么时候能拿到3月12日的分红吗?","text":"$吉利德科学(GILD)$请问知道什么时候能拿到3月12日的分红吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/965759396","isVote":1,"tweetType":1,"viewCount":1246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965119268,"gmtCreate":1583933376954,"gmtModify":1704351606364,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问美股分红像A股一样自动到账吗?","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问美股分红像A股一样自动到账吗?","text":"$吉利德科学(GILD)$请问美股分红像A股一样自动到账吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/965119268","isVote":1,"tweetType":1,"viewCount":2858,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":924067429,"gmtCreate":1588168467461,"gmtModify":1704366734688,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>有效和特效应该还是有些区别,对吗?","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>有效和特效应该还是有些区别,对吗?","text":"$吉利德科学(GILD)$有效和特效应该还是有些区别,对吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/924067429","isVote":1,"tweetType":1,"viewCount":1880,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965119268,"gmtCreate":1583933376954,"gmtModify":1704351606364,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问美股分红像A股一样自动到账吗?","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问美股分红像A股一样自动到账吗?","text":"$吉利德科学(GILD)$请问美股分红像A股一样自动到账吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/965119268","isVote":1,"tweetType":1,"viewCount":2858,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":965759396,"gmtCreate":1584084281015,"gmtModify":1704352949031,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问知道什么时候能拿到3月12日的分红吗?","listText":"<a href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>请问知道什么时候能拿到3月12日的分红吗?","text":"$吉利德科学(GILD)$请问知道什么时候能拿到3月12日的分红吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/965759396","isVote":1,"tweetType":1,"viewCount":1246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":953081940,"gmtCreate":1590061243580,"gmtModify":1704191668779,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>做药本来就是周期长","listText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>做药本来就是周期长","text":"$康希诺生物-B(06185)$做药本来就是周期长","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/953081940","isVote":1,"tweetType":1,"viewCount":1528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":959755597,"gmtCreate":1590038875619,"gmtModify":1704191578992,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>什么情况?","listText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物-B(06185)$</a>什么情况?","text":"$康希诺生物-B(06185)$什么情况?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/959755597","isVote":1,"tweetType":1,"viewCount":1259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":650107841,"gmtCreate":1678951431083,"gmtModify":1678952120266,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"不知道收到邀请的个人和公司有反馈吗?","listText":"不知道收到邀请的个人和公司有反馈吗?","text":"不知道收到邀请的个人和公司有反馈吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650107841","repostId":"1112765790","repostType":2,"repost":{"id":"1112765790","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据,旨在帮助投资者理解世界,做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1678947353,"share":"https://www.laohu8.com/m/news/1112765790?lang=&edition=full","pubTime":"2023-03-16 14:15","market":"other","language":"zh","title":"百度集团大幅跳水!正式推出大语言模型“文心一言”","url":"https://stock-news.laohu8.com/highlight/detail?id=1112765790","media":"老虎资讯综合","summary":"3月16日,百度集团跌超6%,百度正式推出大语言模型“文心一言”。百度正式发布“文心一言”,百度CEO李彦宏介绍,内测中“文心一言”并不完美,但市场有需求必须要推出来。文心一言有五大能力,文学创作、商","content":"<html><head></head><body><p>3月16日,百度集团跌超6%,<b>百度正式推出大语言模型“文心一言”</b>。<img src=\"https://static.tigerbbs.com/f3952304dbb42e79d75c81966fbd6174\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"/>百度正式发布“文心一言”,百度CEO李彦宏介绍,内测中“文心一言”并不完美,但市场有需求必须要推出来。文心一言有五大能力,文学创作、商业文案创作、数理逻辑推算、中文理解、多模态生成。<img src=\"https://static.tigerbbs.com/22be275af4710b944c5d380d52333a49\" tg-width=\"1383\" tg-height=\"645\" referrerpolicy=\"no-referrer\"/>被称为中国版ChatGPT的百度文心一言,今日14:00在百度北京总部大楼正式发布,百度同时在上海张江人工智能岛百度飞桨中心设立发布会分会场。</p><p>百度创始人李彦宏亲自出席发布会并进行文心一言产品介绍,他在开场白中表示:百度文心一言“十月怀胎“,终于”一朝分娩”。据了解,百度已经连续多日进行持续到凌晨的压力测试,为了支持文心一言,亚洲目前最大的单体智算中心山西阳泉百度智算中心,已经将算力提升到每秒可以完成400亿亿次浮点运算,将与百度在江苏盐城等地的其他几座智算中心一起,为“文心一言”提供算力支持。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百度集团大幅跳水!正式推出大语言模型“文心一言”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百度集团大幅跳水!正式推出大语言模型“文心一言”\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2023-03-16 14:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>3月16日,百度集团跌超6%,<b>百度正式推出大语言模型“文心一言”</b>。<img src=\"https://static.tigerbbs.com/f3952304dbb42e79d75c81966fbd6174\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"/>百度正式发布“文心一言”,百度CEO李彦宏介绍,内测中“文心一言”并不完美,但市场有需求必须要推出来。文心一言有五大能力,文学创作、商业文案创作、数理逻辑推算、中文理解、多模态生成。<img src=\"https://static.tigerbbs.com/22be275af4710b944c5d380d52333a49\" tg-width=\"1383\" tg-height=\"645\" referrerpolicy=\"no-referrer\"/>被称为中国版ChatGPT的百度文心一言,今日14:00在百度北京总部大楼正式发布,百度同时在上海张江人工智能岛百度飞桨中心设立发布会分会场。</p><p>百度创始人李彦宏亲自出席发布会并进行文心一言产品介绍,他在开场白中表示:百度文心一言“十月怀胎“,终于”一朝分娩”。据了解,百度已经连续多日进行持续到凌晨的压力测试,为了支持文心一言,亚洲目前最大的单体智算中心山西阳泉百度智算中心,已经将算力提升到每秒可以完成400亿亿次浮点运算,将与百度在江苏盐城等地的其他几座智算中心一起,为“文心一言”提供算力支持。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/0cb3c6c3c55603d00a14ee3389850b7f","relate_stocks":{"09888":"百度集团-SW","BIDU":"百度"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112765790","content_text":"3月16日,百度集团跌超6%,百度正式推出大语言模型“文心一言”。百度正式发布“文心一言”,百度CEO李彦宏介绍,内测中“文心一言”并不完美,但市场有需求必须要推出来。文心一言有五大能力,文学创作、商业文案创作、数理逻辑推算、中文理解、多模态生成。被称为中国版ChatGPT的百度文心一言,今日14:00在百度北京总部大楼正式发布,百度同时在上海张江人工智能岛百度飞桨中心设立发布会分会场。百度创始人李彦宏亲自出席发布会并进行文心一言产品介绍,他在开场白中表示:百度文心一言“十月怀胎“,终于”一朝分娩”。据了解,百度已经连续多日进行持续到凌晨的压力测试,为了支持文心一言,亚洲目前最大的单体智算中心山西阳泉百度智算中心,已经将算力提升到每秒可以完成400亿亿次浮点运算,将与百度在江苏盐城等地的其他几座智算中心一起,为“文心一言”提供算力支持。","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":964434713,"gmtCreate":1584442921432,"gmtModify":1704354152797,"author":{"id":"3491802181757368","authorId":"3491802181757368","name":"DDZ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"50%成功率不差吧","listText":"50%成功率不差吧","text":"50%成功率不差吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/964434713","repostId":"1150330379","repostType":2,"repost":{"id":"1150330379","pubTimestamp":1584440319,"share":"https://www.laohu8.com/m/news/1150330379?lang=&edition=full","pubTime":"2020-03-17 18:18","market":"us","language":"zh","title":"“人民的希望”瑞德西韦让业界专家大失所望!","url":"https://stock-news.laohu8.com/highlight/detail?id=1150330379","media":"全球医生组织 ","summary":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!\n这是最新传播方式认知:\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染","content":"<p><b>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!</b></p>\n<p><b>这是最新传播方式认知:</b></p>\n<p><img src=\"https://static.tigerbbs.com/5178d780395c6aeebadc23d7d1d846c3\"></p>\n<p>根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据,给出最乐观说法是「好坏参半或不及50%效果」。</p>\n<p>华尔街资深分析师表示在评估该项12名患者临床试验报告数据后,得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要!</p>\n<p>相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学,临床病程和病毒学特征,包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的,确诊患者是从钻石公主号游轮接回来的患者。</p>\n<p>该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验,结果表明患者在疾病确诊后第二周出现恶化迹象。」</p>\n<p><b>具体讲,与未接受瑞德西韦治疗的患者相比,接受该药治疗患者的给氧需求,发烧和病毒感染症状改善之间没有「明显时间关联性」。</b></p>\n<p>该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险),这表明该抗病毒治疗效果需要更长时间监测和观察。</p>\n<p>随着疫情全球大流行爆发,寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者,预期1-2月后才能初步评估安全性。</p>\n<p>吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前,在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品,本月底或下月初陆续还会有相关结果报道。</p>\n<p>业界专家认为新药临床试验,特别涉及目前重大疫情,所有试验药品和每项验证结果都会被反复仔细研究,寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望),包括最初个案例也会作为有价值线索分析。</p>\n<p>美国联邦政府的疫情特别行动小组专家指出,该论文尚未经过同行评审,试验结果还需要最终评估。FDA目前无法接受这样的数据审评。</p>\n<p>该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些;大约42%的患者不需要住院治疗;但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展,仍有待研究」。</p>\n<p>还有业界人士提示该试验结果未经同行评审,在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药,包括类固醇激素和抗生素等。</p>\n<p>此外,吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说,该药应尽快给予患者以避免病情恶化,有可能产生一定效果。</p>\n<p>总之,鉴于目前临床试验小样本量和混合其他药品作用,凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度,最终是否止步于III期试验或「被流产」都是未知数。</p>","source":"lsy1584440308046","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“人民的希望”瑞德西韦让业界专家大失所望!</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“人民的希望”瑞德西韦让业界专家大失所望!\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-03-17 18:18 北京时间 <a href=https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg><strong>全球医生组织 </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!\n这是最新传播方式认知:\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据,给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后,得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要!\n相关...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://mp.weixin.qq.com/s/UYbwXhi1OUbBjVs0_jJ4Lg","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150330379","content_text":"被媒体热捧为「人民的希望」抗病毒药瑞德西韦(remdesivir),最新临床试验数据初步评估,让业界人士大失所望!\n这是最新传播方式认知:\n\n根据RBC资本市场权威分析师审议美国12例确诊新冠病毒感染患者的临床试验数据,给出最乐观说法是「好坏参半或不及50%效果」。\n华尔街资深分析师表示在评估该项12名患者临床试验报告数据后,得出结论是「不确定该抗病毒药是否会成功」。该结论对投资者至关重要!\n相关临床研究论文已发表在预印本服务器上。论文详述了12例新冠病毒患者的流行病学,临床病程和病毒学特征,包括3例接受瑞德西韦的治疗结果。该临床试验是由美国CDC应急小组人员开展的,确诊患者是从钻石公主号游轮接回来的患者。\n该报告称「对早期确诊的轻至中度新冠病毒感染患者进行了随机双盲对比治疗性试验,结果表明患者在疾病确诊后第二周出现恶化迹象。」\n具体讲,与未接受瑞德西韦治疗的患者相比,接受该药治疗患者的给氧需求,发烧和病毒感染症状改善之间没有「明显时间关联性」。\n该报告还陈述了服用瑞德西韦的患者出现恶心、呕吐、直肠出血和肝酶升高等不良反应(肝酶改变提示肝毒性潜在风险),这表明该抗病毒治疗效果需要更长时间监测和观察。\n随着疫情全球大流行爆发,寻找药物治疗方法已经和疫苗研发同步进行了。今天由美国国立卫生研究院附属过敏与感染疾病研究所(NIH-NIAID) 主持的疫苗临床试验正式注射给第一位健康者,预期1-2月后才能初步评估安全性。\n吉利德研发的瑞德西韦是在去年埃博拉III期临床试验失败后被重新启用测试的。目前,在美国和中国还有其他4-5项临床试验同时进行中。吉利德也根据「同情法案」为数百名患者提供了该试验药品,本月底或下月初陆续还会有相关结果报道。\n业界专家认为新药临床试验,特别涉及目前重大疫情,所有试验药品和每项验证结果都会被反复仔细研究,寻找可能的有效迹象。因为无数患者期待着哪怕是微小希望(人民的希望),包括最初个案例也会作为有价值线索分析。\n美国联邦政府的疫情特别行动小组专家指出,该论文尚未经过同行评审,试验结果还需要最终评估。FDA目前无法接受这样的数据审评。\n该论文作者指出「在美国确诊的患者总体疾病过程似乎比在中国观察到的患者要好些;大约42%的患者不需要住院治疗;但也提醒这一病情状况是否代表不同医疗水平或病毒谱系本身不断发演变展,仍有待研究」。\n还有业界人士提示该试验结果未经同行评审,在这种情况下各种已知药物引起的副作用可能会比通常情形下低很多。专家专家认为这是因为许多确诊患者已经服用了多种其他药,包括类固醇激素和抗生素等。\n此外,吉利德的「同情用药」通常针对病情恶化的患者。资深专家认为此药仍有可能缓减患者病情恶化。换句话说,该药应尽快给予患者以避免病情恶化,有可能产生一定效果。\n总之,鉴于目前临床试验小样本量和混合其他药品作用,凸显了评估该药临床疗效的难度。希望「纯粹」双盲对照试验也有相当难度,最终是否止步于III期试验或「被流产」都是未知数。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}